Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Enteric diseases are intestinal infections caused by a variety of bacteria, viruses and parasites when they enter the body through the mouth or intestinal systems such as salmonella, shigella, giardia lamblia, campylobacter, cryptosporidium and vibrio cholerae causing salmonellosis, shigellosis, giardiasis, campylobacteriosis, cryptosporidiosis and cholera, respectively.
The global enteric disease testing market is estimated to account for US$ 4,432.7 Mn in terms of value by the end of 2027.
Global Enteric Disease Testing Market: Drivers
High incidence of cholera is expected to propel growth of the global enteric disease testing market over the forecast period. For instance, according to United Nations High Commissioner for Refugees, in 2019, torrential rains and widespread flooding across Yemen led to more than 364,000 suspected cases of cholera and 639 deaths reported since the beginning of the year.
Moreover, outbreak of enteric disease is expected to boost demand for enteric disease testing. For instance, in August 2020, a salmonella outbreak was reported in 47 states in the U.S. The Centers for Disease Control and Prevention reported the number of reported cases of salmonella newport illnesses had grown to 869 cases, with 116 hospitalizations in 47 states in the third week of August.
North America held dominant position in the global enteric disease testing market in 2019, accounting for 38.5% share in terms of value, followed by Europe and Asia Pacific, respectively.
Figure 1: Global Enteric Disease Testing Market Share (%) Value, By Region, 2019
Global Enteric Disease Testing Market: Restraints
Lack of awareness regarding enteric disease, especially in emerging economies, is expected to hinder growth of the global enteric disease testing market.
Moreover, most of the people infected with enteric pathogens are asymptomatic or show mild symptoms. Mild nature of diseases let people ignore its diagnosis. Although, asymptomatic or mild nature of enteric diseases is good for human being but on the other hand it is considered as one of the major restraints affecting growth of the global enteric disease testing market.
Enteric Disease Testing Market Report Coverage
||Market Size in 2019:
||US$ 3,643.4 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 4,432.7 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
- Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: North Africa, Central Africa, South Africa
- By Diseases Type: E. coli Infection, Salmonellosis, Campylobacteriosis, Rotavirus Infection, Cryptosporidiosis, Norovirus Infection, Cholera, C. difficile, H. pylori, Amebiasis, Shigellosis.
Alere, Inc., Becton Dickinson & Company, Biomerica, Inc., bioMerieux, Bio-Rad, Cepheid, Coris BioConcept, DiaSorin, Meridian Bioscience, Inc., Quest Diagnostics, and Trinity Biotech
- Increasing prevalence of enteric diseases
- Approval and launch of new products
|Restraints & Challenges:
- Low awareness in developing economies
Global Enteric Disease Testing Market: Opportunities
Development of vaccines for bovine enteric diseases is expected to offer lucrative growth opportunities for players in the global enteric disease testing market. Diarrhea in calves may be highly fatal. If scours do not respond to commercial vaccines, autogenous vaccines may help.
Moreover, R&D in enteric diseases is also expected to boost demand for enteric disease testing. For instance, The International Centre for Diarrhoeal Disease Research, Bangladesh, and Emory University of the United States conducted studies in April 2017–January 2018 and April–October 2019 and found a high concentration of pathogens such as Escherichia coli, norovirus, Vibrio cholerae, shigella, Salmonella typhi and giardia in Bangladesh.
The global enteric disease testing market was valued at US$ 3,643.4 Mn in 2019 and is forecast to reach a value of US$ 4,432.7 Mn by 2027 at a CAGR of 2.5% between 2020 and 2027.
Figure 2: Global Enteric Disease Testing Market Value (US$ Mn), 2016 – 2027
Market Trends/Key Takeaways
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in October 2019, Mobidiag Ltd., a molecular diagnostics company, received CE marking for its Novodiag Stool Parasites test. The new test is used for the detection of intestinal parasites directly from stool samples.
Outbreak of campylobacter infection is expected to propel growth of the global enteric disease testing market. For instance, in August 2020, Lindsay Farm, New Zealand, recalled raw drinking milk in New Zealand after one person needed hospital treatment for a Campylobacter infection.
Global Enteric Disease Testing Market: Competitive Landscape
Major players operating in the global enteric disease testing market include, Alere, Inc., Becton Dickinson & Company, Biomerica, Inc., bioMerieux, Bio-Rad, Cepheid, Coris BioConcept, DiaSorin, Meridian Bioscience, Inc., Quest Diagnostics, and Trinity Biotech.
Global Enteric Disease Testing Market: Key Developments
Major players in the global enteric disease testing market are focused on approval and launch of new products to expand their product portfolio. For instance, in March 2019, ERADA Technology Alliance Ltd. (ERADA) launched saliva-based diagnostic tool, Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART), for detection of parasites causing malaria.